INNATE PHARMA SP.ADR/1 (IDDA) — Strategic Asset Allocation Index
INNATE PHARMA SP.ADR/1 (IDDA) has a Strategic Asset Allocation Index of 202.0% as of June 2025. Strategic assets (PP&E of €- plus long-term investments of €10.39 Million) total €10.39 Million, measured against net assets of €5.14 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
INNATE PHARMA SP.ADR/1 Strategic Asset Allocation Index (2021–2024)
This chart shows how INNATE PHARMA SP.ADR/1's Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 202.0%, representing strategic assets of €10.39 Million against net assets of €5.14 Million EUR. Explore INNATE PHARMA SP.ADR/1 cash conversion from operations to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for INNATE PHARMA SP.ADR/1 (2021–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for INNATE PHARMA SP.ADR/1 from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of INNATE PHARMA SP.ADR/1.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 116.4% | €10.28 Million | €- | €10.28 Million | €8.83 Million | ▲ +97.5 pp |
| 2023 | 18.9% | €9.80 Million | €- | €9.80 Million | €51.90 Million | ▼ -46.0 pp |
| 2022 | 64.9% | €35.12 Million | €- | €35.12 Million | €54.15 Million | ▲ +27.7 pp |
| 2021 | 37.1% | €39.88 Million | €- | €39.88 Million | €107.44 Million | — |